Drug Profile
Research programme: anti-transferrin receptor 1 antibodies - Perseus Proteomics
Alternative Names: TSP-A74Latest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator Perseus Proteomics
- Class Antineoplastics; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; CD71 antigen modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for preclinical development in Cancer in Japan (Parenteral)
- 03 Dec 2016 Preclinical trials in Cancer in Japan (Parenteral) before December 2016
- 03 Dec 2016 Pharmacodynamics data from a preclinical study in Haematological malignancies presented at the 58th Annual Meeting and Exposition of the American Society of Hematology